-VEGF is known to be an endothelial cell mitogen that stimulates angiogenesis by promoting endothelial cell survival, proliferation, migration, and differentiation. Recent studies have suggested that VEGF may play a pivotal role in glomerular sclerosis through extracellular matrix protein (ECM) accumulation, although the signaling mechanism is still unclear. The GTPase RhoA has been implicated in VEGF-induced type IV collagen accumulation in some settings. Here we study the role of different VEGF receptors and membrane microdomain caveolae in VEGF-induced RhoA activation and fibronectin upregulation in mesangial cells (MCs). In primary rat MC, VEGF time and dose dependently increased fibronectin production. Rho pathway inhibition blocked VEGF-induced fibronectin upregulation. VEGF-induced RhoA activation was prevented by disrupting caveolae with cholesterol depletion and rescued by cholesterol repletion. VEGF stimulation led to a markedly increased VEGFR2/caveolin-1 but failed to increase VEGFR1/caveolin-1 association. VEGF also increased caveolin-1/Src association and activated Src, and Src inhibitor blocked RhoA activation and fibronectin upregulation. Srcmediated phosphorylation of caveolin-1 on Y14 has also been implicated in signaling responses. Overexpression of nonphosphorylatable caveolin-1 Y14A prevented VEGF-induced RhoA activation and fibronectin upregulation. In vivo, although VEGFR1 and VEGFR2 protein levels were both increased in the kidney cortices of diabetic rats, VEGFR2/caveolin-1 association but not VEGFR1/caveolin-1 association was significantly increased. In conclusion, VEGF-induced RhoA activation and fibronectin upregulation require caveolae and caveolin-1 interaction with VEGFR2 and Src. Interference with caveolin/-ae signaling may provide new avenues for the treatment of fibrotic renal disease. extracellular matrix; glomerular sclerosis; caveolin-1 MESANGIAL EXTRACELLULAR MATRIX protein (ECM) accumulation is considered to be a major hallmark of diabetic nephropathy (21, 24, 25, 36, 38) ; however, little is known regarding the molecular mechanisms mediating glomerular ECM accumulation. A variety of cytokines are involved in mesangial matrix expansion, including vascular endothelial growth factor (VEGF), an angiogenic polypeptide that is also known to enhance endothelial cell permeability and differentiation (4, 18) . Recent studies have suggested that VEGF may play a central role in the pathogenesis of diabetic nephropathy through glomerular hypertrophy and ECM production (1, 32, 52, 60, 66) , although the precise signaling mechanism remains largely unknown.
There are three known VEGF receptors expressed in mesangial cells (MCs), VEGFR1/fms-related tyrosine kinase 1 (Flt1), VEGFR2/kinase insert domain receptor (KDR), and neuropilin-1 (59) . VEGF elicits its biological functions by activating specific transmembrane receptors VEGFR1 and VEGFR2 with intrinsic tyrosine kinase activity (54) . Neuropilin-1 has no tyrosine kinase activity, which enhances binding of VEGF 165 to VEGFR2 (55) . The specific function of each receptor subtype is still poorly defined, and little is known about the signal transduction pathways for ligand-receptor interaction.
Caveolae are specialized plasma membrane microdomains morphologically defined as 50-to 100-nm omega-shaped invaginations by electron microscopy (14, 44, 53) . They are most abundant in terminally differentiated cell types (27, 43) , including MCs (42, 58) . Caveolin-1 is the principal residual protein of this membranous structure (43) . Recently, several tyrosine kinase receptors have been shown to be localized in caveolae, including platelet-derived growth factor receptor (PDGFR; Ref. 35) , epidermal growth factor receptor (10, 39) , and VEGFR (2). Caveolin-1 is known to function as a scaffolding protein directly interacting with various signaling molecules and integrates specific transmembrane signaling pathways in the caveolae (34) , including the VEGF signaling pathway (22, 29, 31, 33) . It has been reported that both overexpression of exogenous caveolin-1 and downregulation of endogenous caveolin-1 significantly reduce VEGF-induced ERK2/1 activation, proliferative response, and tube formation in ovine fetoplacental artery endothelial (oFPAE) cells, which demonstrates a paradoxical role of caveolin-1/caveolae in VEGF-induced angiogenic responses (31) . These data are different from previous studies showing that caveolin-1 may play as a negative regulator of VEGFR2 activity in VEGF-induced signaling in bovine aortic endothelial cells (BAECs; Ref. 29) . The role of caveolin-1 in the VEGF signaling pathway in endothelial cells is thus controversial, and the involvement of caveolae /caveolin-1 in VEGF signaling in MCs, however, has not been assessed. Therefore, in the current study, we investigated the role of caveolae/caveolin-1 in VEGF-induced ECM accumulation in MCs.
The small GTPase RhoA has been implicated in VEGFinduced ECM production in MCs (67), but upstream regulators mediating RhoA activation are not yet known. We have recently shown that mechanical stress and transforming growth factor-␤ (TGF-␤)-induced RhoA activation requires caveolae in MCs (46) . In particular, we explored the potential role of caveolae/caveolin-1 in VEGF-induced RhoA activation leading to ECM accumulation.
MATERIALS AND METHODS
Cell culture. Primary MCs were obtained from glomeruli of SpragueDawley rats (Animal Center, Wuhan University, China) by differential sieving and cultured in DMEM, 5.6 mmol/l glucose, supplemented with 20% fetal calf serum (Invitrogen), streptomycin (100 g/ml), and penicillin (100 U/ml) at 37°C in 95% air-5% CO 2. Experiments were carried out using cells between passages 6 -15. Confluent MCs were made quiescent by incubation for 24 h in serum-free medium before treatment. Recombinant human VEGF 165 (Peprotech) was used at 50 ng/ml. Pharmacologic inhibitors were added at the indicated concentrations and times before VEGF: SU5416 (Sigma), 5 mM for 60 min; HA-1077 (Sigma), 25 M for 30 min; cyclodextrin (Calbiochem), 5 mM for 60 min; filipin III (Sigma), 2.5 g/ml for 10 min; cholesterol (Sigma), 15 g/ml for 60 min; and SU6656 (Sigma), 10 M for 30 min.
Protein extraction and Western blot. Cells or kidney cortices were lysed, and protein was extracted as published previously (28) . Briefly, cells were lysed in buffer containing 50 mM Tris pH 7.4, 150 mM NaCl, 1% Triton X-100, 10% glycerol, 5 mM EDTA, 100 M sodium vanadate, 1 mM ␤-glycerophosphate, 1 mM sodium fluoride, 2 g/ml leupeptin, 10 g/ml aprotinin, and 1 mM PMSF. Lysates were collected and centrifuged at 4°C, 14,000 rpm for 10 min to pellet cell debris. The supernatant (50 g) was separated on SDS-PAGE, and Western blot was performed as described previously (28) . Antibodies used included monoclonal fibronectin (1:5,000; BD Biosciences), monoclonal RhoA (1:500; Santa Cruz), monoclonal caveolin-1 (1: 1,000; Upstate), monoclonal phospho-caveolin-1 Y14 (1:1,000; BD Biosciences), monoclonal VEGFR1 (1:500; Santa Cruz), monoclonal VEGFR2 (1:500; Santa Cruz), polyclonal phospho-SrcY416 (1:1,000; Cell Signaling), polyclonal Src (1:1,000; Cell Signaling), and monoclonal ␤-actin (1:5,000; Sigma). For assessment of secreted fibronectin, conditioned medium was collected and centrifuged (4,000 rpm, 5 min) to pellet debris, and 10 g of protein were separated on a 7.5% gel. Membranes were probed with monoclonal anti-fibronectin.
Immunoprecipitation. Cells or kidney cortices were lysed with lysis buffer that included 60 mM N-octyl-glucopyranoside as published previously (28) . After clarification, equal amounts of lysate were incubated overnight with 2 g of primary antibody rotating at 4°C, followed by 25 l of protein G-agarose slurry for 1.5 h at 4°C. Immunoprecipitates were extensively washed, resuspended in 2ϫ sample buffer, boiled, and analyzed by immunoblotting.
RhoA pull-down assay. This was performed as described previously (28) . Briefly, cells were lysed in hypertonic buffer, and GTP-bound RhoA was immunoprecipitated from cleared lysate with 25 l of GST-tagged rhotekin RhoA binding domain bound to glutathioneagarose (Cytoskeleton). Beads were washed, and the immunoprecipitate was resolved on 15% SDS-PAGE. Membranes were probed with anti-RhoA antibody. Lysate (40 g) also was probed for RhoA to ensure equality across conditions.
Transmission electron microscopy. Cultures were fixed with 2.5% glutaraldehyde, postfixed with 1% osmiumetroxide, and then stained en bloc with 2% aqueous uranyl acetate. Fixed cultures were then dehydrated. Silver-gold ultrathin sections were collected parallel to the culture monolayer and mounted on Formvar-coated carbon stabilized 1 ϫ 2 mm slot grids. Samples were counterstained with lead citrate and viewed with a Hitachi H 600 transmission electron microscope at 40 -80 kV.
Transfection. Rat caveolin-1 was amplified from MCs cDNA and inserted into the vector pEGFP-C1 with an NH2-terminal enhanced green fluorescent protein (EGFP). With the use of this as template, Y14 was mutated to alanine. Rat MCs were transfected with empty vector or pEGFP-Cav-1Y14A using Effectene (Qiagen). At 18 -24 h posttransfection, the medium was changed to 0% fetal calf serum and the experiment proceeded.
Animal studies. All animal care and experiments were conducted in accordance with the official recommendations of the Chinese Community Guidelines, and the study was approved by the National Natural Science Foundation of China. Experiments were performed with male Sprague-Dawley rats weighing 200 -225 g (Animal Center, Wuhan University, China). Diabetes was induced with 55 mg/kg streptozotocin (Sigma) injection by tail vein (n ϭ 10). Control rats (n ϭ 10) received equal volume of 0.1 mol/l citrate buffer, pH 4.5.
Hyperglycemia (blood glucose Ͼ20 mmol/l) was confirmed 3 days after injection. All rats had free access to regular lab chow and water. Diabetic rats also received low dose of insulin if required to prevent ketonuria as assessed by dipstick (Bayer Multistix) but to maintain hyperglycemia Ͼ20 mmol/l. After 32 wk, weight and serum glucose were obtained. Rats were then anesthetized for kidney removal. A small cortical section was placed into 10% formaldehyde for immunohistochemistry. Protein was extracted from isolated cortex for Western blot and immunoprecipitation.
Statistical analysis. Densitometry was quantified by a Bio-Rad model GS-670 imaging densitometer. Statistical significance of results was assessed by one-way ANOVA with Tukey's honestly significant difference test for post hoc analysis for experiments (SPSS 17.0 for Windows). P Ͻ 0.05 is considered significant. Data are expressed as means Ϯ SE. Experiments were repeated multiple times, with n as the number of repetitions.
RESULTS

VEGF-induced fibronectin upregulation depends on RhoA/
Rho kinase activation. VEGF has been shown to induce increased type IV collagen production in rat MCs (56, 65) . Treatment with recombinant mouse VEGF 164 increased collagen and fibronectin mRNA expression in murine MCs (64) . We further confirmed the effect of recombinant human VEGF 165 (VEGF) on fibronectin protein levels in rat MCs by Western blot analysis. As illustrated in Fig. 1A , MCs exposed to incremental concentrations of VEGF exhibited significant increase in fibronectin protein levels. Figure 1B showed a time-dependent increase in fibronectin protein levels in MCs, significant by 6 h and seen through 24 h. We also tested fibronectin secretion in response to VEGF, which indicated that VEGF induced fibronectin secretion into the medium in MCs, started from 6 h, and continued to 24 h (Fig. 1B) . We next tested whether the activity of VEGFRs was required for fibronectin upregulation. Pretreatment with a VEGFR tyrosine kinase inhibitor SU5416 (5 mM) inhibited VEGF-induced fibronectin upregulation in MCs, showing the role of VEGFR in VEGF-induced fibronectin accumulation (Fig. 1C) .
VEGF has been shown to activate RhoA in MCs, and RhoA activation has been implicated in VEGF-induced upregulation of the matrix protein collagen IV (67) . The involvement of RhoA activation in VEGF-induced fibronectin upregulation, however, has not yet been assessed. To decipher whether RhoA/Rho kinase mediates VEGF-induced fibronectin accumulation, MCs were exposed to VEGF (50 ng/ml) in the presence of the Rho kinase inhibitor HA-1077, and fibronectin protein levels were assessed by Western blot. The data in Fig.  1D showed that VEGF stimulation failed to increase fibronectin protein levels in HA-1077-pretreated cells, indicating a critical role for RhoA/Rho kinase activation in VEGF-induced fibronectin upregulation.
Caveolae are critical for VEGF-induced RhoA activation. Because RhoA has been found to reside in caveolae in MCs (45) and we have also shown that caveolae mediates RhoA/Rho kinase activation and fibronectin accumulation in response to TGF-␤ (46), we thus next examined the affects of caveolar disruption on VEGF-induced RhoA activation and fibronectin accumulation. We used the membrane-impermeable cholesterol-binding agent cyclodextrin, which depletes cell surface cholesterol, and the membrane-permeable agent filipin III to perturb the formation of caveolae (51, 62) . We observed that both cyclodextrin and filipin prevented VEGF-induced RhoA activation ( Fig. 2A) . We further tested whether the effect of cyclodextrin was reversible by coin-cubation with excess cholesterol. As shown in Fig. 2A , cholesterol reversed the effects of cyclodextrin on RhoA activation. Similar results were observed for fibronectin protein upregulation (Fig.  2B ). These data suggest that VEGF-induced RhoA activation and fibronectin upregulation depend on the structural integrity of caveolae in MCs.
Both VEGFR1 and VEGFR2 receptor proteins have been detected in MCs (57, 59) . However, little is known about the Fig. 1 . Vascular endothelial growth factor (VEGF) induces significant increase in fibronectin protein levels. Mesangial cells (MCs) were treated for the indicated concentrations (A) and times (B) with VEGF and fibronectin protein levels were assessed by Western blot, with actin used as loading control (fibronectin, 240 kDa; actin, 45 kDa; *P Ͻ 0.05 vs. control; n ϭ 5). C: MCs were pretreated with a VEGFR tyrosine kinase inhibitor SU5416 (5 mM, 60 min) and treated with 50 ng/ml VEGF for 6 h, and fibronectin protein levels were assessed by Western blot (*P Ͻ 0.05 vs. other groups; n ϭ 6). D: MCs were pretreated with the Rho kinase inhibitor HA-1077 (HA; 25 M, 30 min) and treated with 50 ng/ml VEGF for 6 h, and fibronectin protein levels were assessed by Western blot (*P Ͻ 0.05 vs. other groups; n ϭ 6). Fig. 2 . Caveolar disruption prevents VEGFinduced RhoA activation and fibronectin accumulation. MCs were treated with VEGF (50 ng/ml) in the presence or absence of pretreatment with the caveolar-disrupting agent cyclodextrin (CD; 5 mM, 60 min) or filipin (2.5 g/ml, 10 min). Reversal of drug effects was sought with simultaneous cholesterol repletion (Chol; 15 g/ml) given at the time of cyclodextrin administration. A: RhoA activity was assessed by pull-down assay of GTP-bound RhoA (24 kDa) as described in MATERIALS AND METHODS (*P Ͻ 0.05 vs. control; #P Ͻ 0.05 vs. VEGF; n ϭ 4). B: fibronectin protein levels were assessed by Western blot (*P Ͻ 0.05 vs. control; #P Ͻ 0.05 vs. VEGF; n ϭ 6). regulation and function of different VEGF receptors. Since VEGF-induced RhoA activation and fibronectin upregulation depends on the activity of VEGFRs and structural integrity of caveolae in MCs, we thus sought to investigate whether VEGF induces the interaction of caveolae /caveolin-1 and VEGFRs. We first tested VEGFR1 and VEGFR2 protein levels in response to VEGF. As illustrated in Fig. 3A , VEGF induced transient VEGFR1 upregulation, which maximized at 30 min and came back to basal levels at 60 min with VEGF treatment. VEGF also induced transient VEGFR2 upregulation, which maximized at 1-5 min and came back to basal levels at 60 min with VEGF treatment (Fig. 3B) . The upregulation of both VEGF receptors raised a key question, i.e., which VEGFR subtype(s) are responsible for mediating fibronectin upregulation? We next examined the interaction of VEGFR1/2 and caveolin-1, the principal residual protein of caveolae, by immunoprecipitation. VEGFR1 has been shown to associate with caveolin-1 in acute myeloid leukemia cells (6) , but it has not been assessed in MCs. We then examined an interaction between VEGFR1 and caveolin-1. As shown in Fig. 3C , VEGFR1 protein was detected in anticaveolin-1 immunoprecipitates in unstimulated MCs. VEGF stimulation failed to increase VEGFR1/caveolin-1 association. It has been reported that VEGFR2 localizes with caveolin-1 in plasma membrane caveolae and binds to caveolin-1 directly in endothelial cells (16, 29, 31) , although this has to date not been demonstrated in MCs. As seen in Fig. 3D , in unstimulated MCs, VEGFR2 protein was detected in anticaveolin-1 immunoprecipitates from protein extracts. The stimulation of MCs with VEGF for 10 min led to a markedly increased VEGFR2/caveolin-1 association and caveolin-1 protein levels. We also investigated the effects of cholesterol depletion on the association of VEGFR1/2 and caveolin-1. The VEGFR2/caveolin-1 association induced by VEGF was markedly reduced with pretreatment with cyclodextrin and filipin (Fig. 3D) , suggesting that the protein association requires the integrity of caveolae structure. These results indicate that VEGFR1 seems not to be the one mediating VEGF-induced RhoA activation and fibronectin upregulation in MCs; instead, this may be principally mediated by VEGFR2/caveolin-1 association and intact caveolae as upstream regulators.
VEGF leads to caveolin-1 upregulation and phosphorylation. Since intact caveolae are important for VEGF-induced VEGFR2/ caveolin-1 association, RhoA activation and fibronectin upregulation, we then asked whether VEGF regulate caveolae and caveolin-1 expression in MCs. A previous report shows that caveolin-1 was downregulated by VEGF and fibroblast growth factor 2 in HUVECs (33) . Interestingly, this is contradictory to Liao et al. (31) , who observed that VEGF and fibroblast growth factor 2 do not alter caveolin-1 protein expression in oFPAE cells. It has not yet been assessed whether VEGF regulate caveolae and caveolin-1 expression in MCs. By Western blot analyses, we observed Fig. 3 . VEGF induces a markedly increased VEGFR2 association with caveolin-1. MCs were treated for the indicated times with 50 ng/ml VEGF, VEGFR1 (180 kDa; A), and VEGFR2 protein levels (180 kDa; B) were assessed by Western blot, with actin used as loading control (*P Ͻ 0.05 vs. control; n ϭ 5). Then, MCs were treated with VEGF (50 ng/ml, 5 min) in the presence or absence of pretreatment with cyclodextrin (5 mM, 60 min) or filipin (2.5 g/ml, 10 min). Reversal of drug effects was sought with simultaneous cholesterol repletion (15 g/ml) given at the time of cyclodextrin administration. Caveolin-1 (24 kDa) was immunopricipitated (IP), and its association with VEGFR1 (C) and VEGFR2 (D) was assessed by Western blot. IB, immunoblot. Actin in the supernatant was probed to ensure equal immunoprecipitation across conditions (*P Ͻ 0.05 vs. control; #P Ͻ 0.05 vs. VEGF; n ϭ 4).
that VEGF rapidly stimulated transient caveolin-1 upregulation, which maximized at 1-5 min with VEGF (50 ng/ml) treatment (Fig. 4A) . Interestingly, the maximal induction of VEGFR2 and caveolin-1 upregulation correlated with the observed VEGFinduced association between VEGFR2 and caveolin-1, indicating the role of VEGFR2 in caveolin-1 upregulation. We also found that VEGF induced upregulation of morphologically detectable caveolae as seen by transmission electron microscope (Fig. 4B) . These results demonstrated that VEGF regulated caveolin-1 expression and the formation of caveolar structures in MCs. VEGFinduced upregulation of caveolin-1 also resulted in the increase of cell surface caveolae structure.
Phosphorylation of caveolin-1 at Y14 has been shown to increase with some growth factors such as TGF-␤ (46). The phosphorylation status of caveolin-1 may modulate its interaction with other proteins (5, 26) . We therefore studied whether VEGF regulates caveolin-1 phosphorylation at Y14 in MCs. As shown in Fig. 4A , VEGF induced caveolin-1 Y14 phosphorylation in a time-dependent manner, with a significant increase at 10 min with VEGF (50 ng/ml) treatment.
Because Src kinases are the only known caveolin-1 Y14 kinases (5, 30, 69) and we have previously shown that mechanical stretch or TGF-␤ induce the activation of Src in MCs (45, 46), we next examined whether VEGF leads to Src activation. Figure 5A showed a time-dependent increase in the autophosphorylation of Y416 on Src, indicative of increased Src activity, in response to VEGF. Pretreatment with a VEGFR tyrosine kinase inhibitor SU5416 (5 mM) inhibited VEGF-induced Src activation (Fig.  5B) . Interestingly, VEGF-induced caveolin-1 phosphorylation at Y14 follows the kinetics of Src activation (Fig. 4A) , suggesting that Src activation is the upstream event. Src and its related kinases localize to caveolae in numerous cell types (48), including MCs (45) . We then sought whether caveolin-1 Y14 phosphorylation induced by VEGF was mediated by Src in MCs. As illustrated in Fig. 5C , VEGF led to a significantly increased association between Src and caveolin-1, as determined by immunoprecipitation of caveolin-1 and immunoblotting for Src. Pretreatment with the VEGFR tyrosine kinase inhibitor SU5416 (5 mM) inhibited VEGF-induced Src/caveolin-1 association. Figure 5D shows that Src inhibitor SU6656 prevented VEGFinduced caveolin-1 Y14 phosphorylation and had no affect on VEGF-induced caveolin-1 upregulation. These results suggest that VEGF-induced caveolin-1 phosphorylation at Y14 could be mediated by Src.
VEGF-induced RhoA activation and fibronectin upregulation require src activation and caveolin-1 Y14 phosphorylation. Caveolin-1 Y14 phosphorylation by Src kinases is an upstream event in mechanical stretch or TGF-␤-induced RhoA activation in MCs (45, 46) . Since VEGF also depends on caveolae on RhoA activation, we further investigated the role of Src kinases and caveolin-1 Y14 in this setting. As shown in Fig. 6A , the Src inhibitor SU6656 prevented VEGF-induced RhoA activation at its maximal time of induction (30 min). Figure 6B showed that SU6656 prevented VEGF-induced fibronectin upregulation.
To investigate whether caveolin-1 phosphorylation mediate VEGF-induced RhoA activation, MCs were transfected with the nonphosphorylatable mutant caveolin-1 Y14A, which was tagged with EGFP. Transfection in MCs was observed with fluorescence microscopy (Fig. 7A) . Overexpression of this construct was shown in Fig. 7B . As seen in Fig. 7C , RhoA activation in response to VEGF, observed in MCs overexpressing the empty vector pEGFP-C1, was clearly abrogated in MCs with caveolin-1 Y14A. Similar results were observed for VEGF-induced fibronectin upregulation (Fig. 7D) . These re- Fig. 4 . VEGF rapidly stimulates caveolin-1 upregulation, caveolin-1 phosphorylation at Y14, and the increase of cell surface caveolae structure. MCs were treated for the indicated times with 50 ng/ml VEGF. A: caveolin-1 protein levels and phosphorylation at Y14 were assessed by Western blot, with actin used as loading control (*P Ͻ 0.05 vs. control; n ϭ 5). B: morphologically detectable caveolae (arrows) were observed by transmission electron microscope. Scale bar 100 ϭ nm. VEGF treatment increased the number of caveolae organelles in MCs (*P Ͻ 0.05 vs. control; n ϭ 5).
sults suggested that VEGF-induced RhoA activation and fibronectin upregulation are dependent on Src activation and caveolin-1 Y14 phosphorylation.
VEGFR2 association with caveolin-1 is markedly increased in diabetic rat kidney cortex. Since VEGFR2 mediated VEGFinduced RhoA activation and fibronectin upregulation by VEGFR2/caveolin-1 association in MCs, we next sought to test if it also occurred in vivo. Type 1 diabetes was induced in SD rats by streptozotocin (STZ) injection, which is characterized by hyperglycemia and low circulating insulin levels. After 32 wk, there was no difference between groups in systolic blood pressure (control: 124.0 Ϯ 6.5 mmHg and STZ: 122.5 Ϯ 7.9 mmHg). Diabetic rats had significantly higher plasma glucose level (control: 3.66 Ϯ 0.42 mmol/l and STZ: 29.11 Ϯ 1.81 Fig. 5 . VEGF leads to Src activation and association with caveolin-1. A: since caveolin-1 Y14 phosphorylation is known to be effected by Src kinases, Src activation in response to VEGF (50 ng/ml) at the indicated times was assessed by Western blot for phosphorylated Src Y416 (60 kDa; *P Ͻ 0.05 vs. control; n ϭ 5). B: effect of pretreatment with the VEGFR tyrosine kinase inhibitor SU5416 (5 mM, 60 min) on VEGF-induced Src activation at 10 min was assessed (*P Ͻ 0.05 vs. others; n ϭ 4). C: MCs were treated with VEGF (50 ng/ml, 10 min), caveolin-1 was immunopricipitated, and its association with Src was assessed by Western blot. D: effect of pretreatment with the Src inhibitor SU6656 (10 M, 30 min) on VEGF-induced caveolin-1 Y14 phosphorylation at 10 min was assessed (*P Ͻ 0.05 vs. others; n ϭ 4). mmol/l; P Ͻ 0.01 vs. control). Immunohistochemistry of cortical sections for VEGFR1 and VEGFR2 showed an increased staining for VEGFR1 and VEGFR2 in diabetic rats compared with control rats (Fig. 8 ). VEGFR1 and VEGFR2 protein levels were also detected by Western blot analysis (Fig. 9, A and B) . Consistent with immunohistochemistry, VEGFR1 and VEGFR2 protein levels were increased in the kidney cortices of diabetic rats. Immunoblots from three separate rats are shown. Next, we assessed the association between VEGFR1/2 and caveolin-1 by immunoprecipitation of caveolin-1 from kidney cortices. As illustrated in Fig. 9C , no difference in VEGFR1/caveolin-1 association was observed between control and diabetic groups. In contrast, VEGFR2/caveolin-1 association was significantly increased in the kidney cortices of diabetic rats (Fig. 9D) . Although we cannot exclude some degree of nonspecific binding of primary antibodies, coupled with our immunoblots in MCs, these data indicate that VEGFR2/caveolin-1 signaling pathway is activated in diabetic nephropathy.
DISCUSSION
VEGF is an important regulator in maintaining normal kidney functions. Recently, it has been reported that VEGF exerts a number of pathophysiologic effects on the kidneys (13, 19, 23, 51, 63) . VEGF and its receptors are upregulated in the diseased kidneys such as diabetic nephropathy and focal segmental glomerulosclerosis (3, 9, 52). VEGF mediates diabetic nephropathy, but its precise role remains to be determined. Increased VEGF involves in glomerular hypertrophy, proteinuria, and ECM production (1, 7, 32, 40, 41) . However, there has been only a small amount of data available concerning the signaling pathways and regulation of the VEGF system. Here, we demonstrate that VEGF-induced RhoA activation and fibronectin upregulation in MCs is mediated by the association of caveolin-1 with VEGFR2 and Src-mediated caveolin-1 phosphorylation. These studies shed light on a novel pathway showing a requirement for caveolae in VEGF-induced ECM production.
It has been reported that both VEGFR1 and VEGFR2 are localized in caveolae in several cell lines (6, 16, 29, 31) . Caveolae have been implicated in VEGF-induced ERK2/1 signaling and permeability in vascular endothelial cells (16, 29, 32) . However, the assessment of the role of caveolin-1/caveolae in VEGF signaling in MCs has not been addressed. Our studies show that caveolae are clearly required for VEGFinduced activation of RhoA and downstream fibronectin synthesis. Caveolin-1 has emerged as a key caveolae-associated protein that regulates the activity of numerous signaling proteins (8, 50) . Caveolin-1 is known to interact with some signaling proteins as a negative regulator (47) . In BAECs, caveolin-1 is associated with the inactive form of VEGFR2 and undergoes rapid dissociation from the receptor upon stimulation with VEGF. This association of caveolin-1 is inhibitory to VEGFR2 activity (29) . Positive effects, however, have also been demonstrated in insulin and TGF-␤ receptor signaling (46, 68) . Thus it seems that caveolae and caveolin-1 lead to different actions depending on the cell type and stimuli. It is unknown whether caveolin-1 is involved in the interaction with VEGFR1 or VEGFR2 in MCs. We examined the association of caveolin-1 with VEGFR1 and VEGFR2 in mediating VEGFinduced fibronectin upregulation. Although VEGF upregulates both VEGFR2 and VEGFR1 in MCs, VEGFR2 is likely the dominant receptor for VEGF-induced fibronectin upregulation because: 1) VEGF stimulation for 10 min led to a markedly increased VEGFR2/caveolin-1 association but failed to increase VEGFR1/caveolin-1 association. The VEGFR2/caveolin-1 association, RhoA activation, and fibronectin upregulation induced by VEGF were markedly reduced with pretreatment with the cholesterol depletion agent cyclodextrin and filipin, suggesting that intact caveolae and VEGFR2/caveolin-1 association as upstream regulators; and 2) the maximal induction (1-5 min) of VEGFR2 and caveolin-1 upregulation correlated with the observed VEGF-induced association (10 min) between VEGFR2 and caveolin-1. These data suggest that VEGFR2 may play a more important role than VEGFR1 in mediating VEGF-induced fibronectin upregulation via caveolin-1 and intact caveolae in MCs. Until now, little is known about the regulation and function of VEGF receptors in renal diseases. VEGFR1 may involve in the inflammatory responses, whereas VEGFR2 predominantly mediates angiogenesis. Recently, Sato et al. (49) observed that selective stimulation of VEGFR2 accelerates progressive renal disease. Overexpressing a mutant form of VEGF-A binding, only VEGFR2 caused mesangial injury with increased proliferation associated with elevated expression of PDGF, PDGF-␤ receptor, and VEGFR2 (49) . Our studies showed that VEGFR1 and VEGFR2 were both enhanced in kidney cortices of diabetic rats and VEGFR2/ caveolin-1 association but not VEGFR1/caveolin-1 association was significantly increased in diabetic kidneys, supporting the role of VEGFR2/caveolin-1 signaling pathway in ECM accumulation identified in our in vitro studies. It also suggests a function of VEGFR2 that is independent of angiogenesis. Further experiments are in progress to evaluate it.
On the other hand, we show that VEGF regulated the protein levels of caveolin-1 and the formation of caveolar structures in MCs. Recent evidence has pointed out caveolae involve the endocytosis of several receptors, such as TGF-␤ receptors and epidermal growth factor receptors (12, 39) . VEGF stimulation also promotes VEGF receptor internalization within caveolae together with endothelial nitric oxide synthase and translocation of both molecules to the nucleus in BAECs and in bovine retinal endothelial cells (17) . Thus the transient upregulation of VEGFR2, caveolin-1 and caveolar structures in MCs may represent a mechanism for VEGF-induced the translocation of VEGFR2 to the nucleus within caveolae.
The Src family kinases are the only kinases known to phosphorylate caveolin-1 at Y14 (5, 30, 69) . Association of caveolin-1 with Src-family kinases has been reported in the signaling pathway required for albumin endocytosis and transcytosis, where activation of an endothelial cell membrane albumin-binding protein (gp60) induced caveolin-1 phosphorylation and association with kinases Src and Fyn (61) . However, caveolin-1 phosphorylation seems to be cell type and stimulus specific because it was not observed in adrenal cortex EC after VEGF stimulation (15) nor in BAEC under shear stress condition (20) , even though this phosphorylation was similarly demonstrated after mechanical stretch or TGF-␤ stimulation in MCs (45, 46) . In our study, VEGF induced a sustained increase in the autophosphorylation of Y416 on Src and caveolin-1 phosphorylation at Y14 and then enabled RhoA activation. Using the specific Src inbitor SU6656 and nonphosphorylatable mutant caveolin-1 Y14A, we show that Src-mediated caveolin-1 phosphorylation is required for downstream fibronectin upregulation. However, the mechanisms involved in the VEGF-dependent phosphorylation of caveolin-1 by Src kinase remain obscure. VEGFR2 protein lacks consensus binding sites for Src SH2 domains (11) . Our data show that VEGF increased VEGFR2/caveolin-1 association and Src/caveolin-1 association in MCs, which suggests that caveolin-1 functions as a scaffolding protein recruiting VEGFR2 and Src. Thus VEGFinduced caveolin-1 phosphorylation at Y14 could be mediated using Src as an intermediary, as was suggested for the TGF-␤ and insulinstimulated tyrosine phosphorylation of caveolin-1 (37, 46) .
The role of caveolin-1 phosphorylation in cell function remains unclear but seems important. Whether caveolin-1 phosphorylation involves its interaction with other components is currently under investigation. We have shown that caveolin-1 phosphorylation on Y14 is necessary for the association between caveolin-1 and RhoA and subsequent RhoA activation in response to TGF-␤ as well as in mechanical stress-induced signaling (45, 46) . Here, we found that phosphorylation on this residue was important for VEGF-induced RhoA activation and fibronectin upregulation using the nonphosphorylatable mutant caveolin-1 Y14A. VEGF-induced collagen synthesis has been shown to require p42/p44 MAPK activation in human MCs or RhoA signaling in rat MCs (1, 67) . Our studies now demonstrate a requirement for caveolin-1 phosphorylation in VEGFinduced RhoA signaling in rat MCs. Whether caveolin-1/ caveolae involves p42/p44 MAPK activation in VEGF-induced matrix upregulation, as well as the relationship between these signaling proteins, needs further study.
In summary, the present study highlights a novel role of caveolin-1/caveolae in VEGF-induced matrix upregulation.
The requirement for Src activation shows the importance of phosphorylation of caveolin-1 in subsequent RhoA activation and fibronectin synthesis. These findings help to elucidate the initial events in RhoA activation by VEGF and suggest potential targets for prevention and delay of the development of mesangial sclerosis marked by excessive VEGF signaling.
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